Navigation Links
Close up look at a microbial vaccination program
Date:9/22/2011

A complex of proteins in the bacterium E.coli that plays a critical role in defending the microbe from viruses and other invaders has been discovered to have the shape of a seahorse by researchers with the U.S Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab). This discovery holds far more implications for your own health than you might think.

In its never-ending battle to protect you from infections by bacteria, viruses, toxins and other invasive elements, your immune system has an important ally many allies in fact. By the time you reach adulthood, some 90-percent of the cells in your body are microbial. These microbes collectively known as the microbiome play a critical role in preserving the health of their human host.

"Perturbations of the human microbiome by viral and other infections can disrupt important symbioses and open the door to invasions by human pathogens," says Blake Wiedenheft, a biochemist with Berkeley Lab and the University of California (UC) Berkeley. "By understanding the mechanisms behind microbial immune systems, we can better understand how they are similar and where they are different from the human immune system."

Wiedenheft is part of a team of researchers, led by biochemist Jennifer Doudna, a leading authority on RNA molecular structures, and biophysicist Eva Nogales, an expert on electron microscopy and image analysis, that has provided the first sub-nanometer look at a central player in the microbial immune system. Through a combination of cryo-electron microscopy and three-dimensional image reconstruction, they have determined the structure of a protein complex called "Cascade," that acts as a surveillance system for detecting and inactivating the nucleic acid of invading pathogens.

Doudna and Nogales are the corresponding authors and Wiedenheft and Gabriel Lander are the lead authors of a paper describing this research in the journal Nature. The
'/>"/>

Contact: Lynn Yarris
lcyarris@lbl.gov
510-486-5375
DOE/Lawrence Berkeley National Laboratory
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. New threat closes in on iconic Galápagos wildlife
2. New discovery brings customized tuberculosis therapies based on genotype closer to reality
3. Discovery of natural antibody brings a universal flu vaccine a step closer
4. Scientists a step closer to understanding natural antifreeze molecules
5. IOF calls for improved strategies to close the treatment gap and reduce future burden of fractures
6. Too close for comfort? Maybe not
7. Closer look at cell membrane shows cholesterol keeping order
8. Getting closer to a better biocontrol for garden pests
9. Study shows hunger hitting closer to home
10. Stem cell therapy for age-related macular degeneration -- a step closer to reality
11. U of M researchers close in on technology for making renewable petroleum
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Close up look at a microbial vaccination program
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Hopkins scientists seems to have discovered an almost-too-easy way to ... potent versions. Their finding, reported this week in Nature, could ... but also other body tissues. What the researchers ... neural stem cells the sort that might be used ...
... The giant panda is not at an evolutionary dead end ... new research involving scientists from Cardiff University. Previous ... requirements and slow reproductive rates have led to a lack ... extinction. Now a study by Professor Michael Bruford ...
... August 23, 2007 On August 16, the Food and ... sold under the brand name Coumadin. The new label suggests ... be safer for patients with variations in two genes, CYP2C9 ... testing, which may be a useful tool in determining appropriate ...
Cached Biology News:When is a stem cell not really a stem cell? 2American College of Medical Genetics responds to new FDA labeling decision for warfarin 2
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)...  CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical ... for the prevention and treatment of cardiorenal and ... July 18, 2014 from the NYSE MKT LLC ... plan to regain compliance with continued listing standards ... is continuing the Company,s listing and has granted ...
(Date:7/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on Potassium ... basic information, including its definition, classification, application, ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis, the ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2Getting More Life out of Lithium-ion Batteries 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... , , ROCKVILLE, Md., ... has announced that 263 regulatory professionals achieved Regulatory Affairs ... RAC credential is administered by RAPS and is the ... product sector. , , (Logo: ...
... BEIJING, Sept. 4 /PRNewswire-Asia/ -- ... provider of biopharmaceutical products in China, announced today that,the ... Republic,of China has issued the initial order to Sinovac ... to the initial order, Sinovac is,required to complete the ...
... September 4 Karolinska Development (publ),today announced that one ... clinical study of its candidate drug, tafoxiparin, a,new drug ... promising results of the Phase II trial bring the ... strategy. , Dilafor,s candidate drug, ...
Cached Biology Technology:263 Regulatory Professionals Achieve RAC Certification 2263 Regulatory Professionals Achieve RAC Certification 3Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 3Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 2Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 3
Request Info...
supplied with 10x reaction buffer...
... from yeast/leuconostoc overproducer ATP: ... EC 2.7.1.1/1.1.1.49. One unit of ... of D-glucose in 1 min ... One unit of G6P-DH will ...
Request Info...
Biology Products: